Sichuan Biokin Pharmaceutical Postpones Hong Kong IPO

MT Newswires Live11-12

Sichuan Biokin Pharmaceutical (HKG:2615, SHA:688506) has decided to postpone its planned Hong Kong initial public offering, scheduled for Nov. 17, citing prevailing market conditions, according to a Wednesday bourse filing.

The Chinese integrated pharmaceutical firm said it will not proceed with the offering as outlined in its November 7 prospectus, and the international and Hong Kong underwriting agreements will not take effect.

Application monies for the Hong Kong public offering will be refunded in full without interest starting November 17, the filing said.

Biokin added that the postponement does not affect its current operations while reassessing a new timetable.

The firm launched its listing last week, aiming to raise up to HK$3.36 billion from the offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582934387?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 11:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582934387","market":"hk","top_or_hot":-1,"title":"Sichuan Biokin Pharmaceutical Postpones Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/688506\">Sichuan Biokin</a> Pharmaceutical (HKG:2615, SHA:688506) has decided to postpone its planned Hong Kong initial public offering, scheduled for Nov. 17, citing prevailing market conditions, according to a Wednesday bourse filing.</p><p>The Chinese integrated pharmaceutical firm said it will not proceed with the offering as outlined in its November 7 prospectus, and the international and Hong Kong underwriting agreements will not take effect.</p><p>Application monies for the Hong Kong public offering will be refunded in full without interest starting November 17, the filing said.</p><p>Biokin added that the postponement does not affect its current operations while reassessing a new timetable.</p><p>The firm launched its listing last week, aiming to raise up to HK$3.36 billion from the offering.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Biokin Pharmaceutical Postpones Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Biokin Pharmaceutical Postpones Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-12 11:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/688506\">Sichuan Biokin</a> Pharmaceutical (HKG:2615, SHA:688506) has decided to postpone its planned Hong Kong initial public offering, scheduled for Nov. 17, citing prevailing market conditions, according to a Wednesday bourse filing.</p><p>The Chinese integrated pharmaceutical firm said it will not proceed with the offering as outlined in its November 7 prospectus, and the international and Hong Kong underwriting agreements will not take effect.</p><p>Application monies for the Hong Kong public offering will be refunded in full without interest starting November 17, the filing said.</p><p>Biokin added that the postponement does not affect its current operations while reassessing a new timetable.</p><p>The firm launched its listing last week, aiming to raise up to HK$3.36 billion from the offering.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688506","symbol_name":"百利天恒","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2582934387","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582934387","pubTimestamp":1762919182,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sichuan Biokin Pharmaceutical  has decided to postpone its planned Hong Kong initial public offering, scheduled for Nov. 17, citing prevailing market conditions, according to a Wednesday bourse filing.The Chinese integrated pharmaceutical firm said it will not proceed with the offering as outlined in its November 7 prospectus, and the international and Hong Kong underwriting agreements will not take effect.Application monies for the Hong Kong public offering will be refunded in full without interest starting November 17, the filing said.Biokin added that the postponement does not affect its current operations while reassessing a new timetable.The firm launched its listing last week, aiming to raise up to HK$3.36 billion from the offering.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688506":"百利天恒","BK0239":"医药制造","02615":"百利天恒"},"translate_title":"四川百奥金药业推迟香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688506":0.9,"02615":1.5},"content_text":"Sichuan Biokin Pharmaceutical (HKG:2615, SHA:688506) has decided to postpone its planned Hong Kong initial public offering, scheduled for Nov. 17, citing prevailing market conditions, according to a Wednesday bourse filing.The Chinese integrated pharmaceutical firm said it will not proceed with the offering as outlined in its November 7 prospectus, and the international and Hong Kong underwriting agreements will not take effect.Application monies for the Hong Kong public offering will be refunded in full without interest starting November 17, the filing said.Biokin added that the postponement does not affect its current operations while reassessing a new timetable.The firm launched its listing last week, aiming to raise up to HK$3.36 billion from the offering.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582934387","isCrawlerRequest":true}